相关实验视频

Updated: Jul 23, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

莱斯塔乌尔提尼布 (CEP-701) 降低了边缘状态的持续时间,在年轻大鼠中

Yara Mrad¹, Reem El Jammal², Helene Hajjar¹

¹Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Epilepsy research

|July 19, 2023

概括

莱斯塔乌尔提尼布 (CEP-701) 显著缩短了 status epilepticus (SE) 持续时间,并减少了大脑损伤. 这种TrkB受体对抗剂在标准治疗失败时显示出作为SE辅助疗法的希望.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
的研究研究.

背景情况:

状态 (SE) 是一种医疗紧急情况,需要立即治疗以防止脑损伤.
目前的抗发作药物在大约30%的儿科病例中是无效的.
与热粒素相关的激酶B (TrkB) 受体在神经元过度兴奋性中起作用.

研究的目的:

调查Lestaurtinib (CEP-701) 是否是一种TrkB受体对抗剂,可以改善SE治疗反应.
为了确定CEP-701是否可以减少与SE相关的脑损伤.

主要方法:

在老鼠中,使用内桃体内酸诱导了状态.
在SE发作15分钟后,老鼠接受了CEP-701或车辆.
标准的抗发作药物 (亚兹帕姆和 levetiracetam) 被给予所有组.
脑组织分析了TrkB二元化,神经元密度和GFAP水平.

主要成果:

与车辆相比,CEP-701治疗将SE持续时间减少了50%.
SE增加了TrkB的二分化,CEP-701阻止了这一效应.
治疗CEP-701导致GFAP水平降低,这表明神经炎症减少.
神经元密度由SE减少,CEP-701和车辆组之间没有显著差异.

结论:

莱斯塔尔提尼布 (CEP-701) 有效地缩短了SE的持续时间,并减轻了相关的大脑损伤.
CEP-701阻止TrkB二元化的能力是其中的一个关键机制.
CEP-701是一种潜在的SE辅助疗法,特别是在治疗耐药的病例中.

关键词:

没有成熟的大脑.莱斯塔乌尔提尼布 (CEP-701) 是一种状态性病的状态治疗方法治疗方法热粒素相关激酶B (TrkB) 受体的受体

更多相关视频

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System

Published on: July 21, 2015

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

相关概念视频

Arteries of the Lower Limbs

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...